Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBINE-AF: Combined PFA and RF Ablation vs PFA Alone for Long-Standing Persistent AF
NCT07633509Not yet recruiting
- Sponsor
- Henan Purui Pharmaceutical
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Randomised, open-label trial in Atrial fibrillation (AFib) (2 arms), sponsored by Henan Purui Pharmaceutical. Primary endpoint: Freedom from Atrial Arrhythmia Recurrence at 12 Months. Planned start Jul 2026; status: not yet recruiting.
02
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07633509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07633509.